Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 4/20 | 0.32 |
| ▸ | JAK1 | P23458 | 4/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27758269 | 0.86 | NOTUM (0.38) | LRRK2FAAHBTKJAK2JAK1 | |
| SCHEMBL26976576 | 0.81 | MGLL (0.39) | LRRK2FAAHBTKJAK2JAK1 | |
| SCHEMBL1407132 | 0.80 | LRRK2 (0.38) | LRRK2FAAHBTKJAK2JAK1 | |
| SCHEMBL1407131 | 0.80 | LRRK2 (0.38) | LRRK2FAAHBTKJAK2JAK1 | |
| SCHEMBL27758258 | 0.79 | BTK (0.40) | LRRK2BTKAADATACHE | |
| SCHEMBL28863344 | 0.79 | BTK (0.43) | BTKJAK2JAK1AADATACHE | |
| SCHEMBL28240637 | 0.78 | BTK (0.51) | BTKJAK2JAK1AADATTYK2 | |
| SCHEMBL26419252 | 0.74 | IRAK4 (0.44) | BTKJAK2JAK1TYK2 | |
| SCHEMBL1407057 | 0.73 | BAZ2B (0.39) | LRRK2JAK1 | |
| SCHEMBL1407059 | 0.73 | BAZ2B (0.39) | LRRK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LRRK2 31/4885FAAH 2797/4885BTK 1981/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LRRK2 31/4885FAAH 2797/4885BTK 1981/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | LRRK2 31/4885FAAH 2797/4885BTK 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.